BIIB vs REGN
BIIB and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BIIBBIOGEN INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $32.00B | — |
| P/E (TTM) | 23.3 | 19.8 |
| P/B | 2.16 | — |
| P/S | 3.2x | — |
| Revenue | $9.94B(TTM) | $15.53B(TTM) |
| Revenue growth (YoY) | 2.2% | 1.0% |
| Net income | $1.37B(TTM) | $4.33B(TTM) |
| Earnings growth (YoY) | -20.8% | 2.1% |
| EPS, diluted | $9.30(TTM) | $40.41(TTM) |
| EBIT margin | 28.7% | 24.9% |
| ROE | 8.7% | 14.2% |
| ROIC | 13.0% | 9.4% |
| Piotroski F | 4/9 | — |
| 1y total return | +64.0% | +37.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BIIB vs REGN
| Metric | BIIB | REGN |
|---|---|---|
| End value | $7.7K | $20.6K |
| Total return | -22.9% | +106.1% |
| CAGR | -2.5% | +7.3% |
| Volatility | 41.3% | 32.2% |
| Sharpe | 0.04 | 0.26 |
| Sortino | 0.07 | 0.38 |
| Max drawdown | -72.7% | -59.7% |
Based on 2600 common trading days, 2016-04-28 → 2026-08-31 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)